NDASUBCUTANEOUSSOLUTION
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
LANREOTIDE ACETATE (lanreotide acetate) by Gen Pharmaceuticals is lanreotide, the active component of lanreotide injection, is an octapeptide analog of natural somatostatin. Approved for acromegaly, neuroendocrine tumours. First approved in 2021.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lanreotide Acetate is a somatostatin analog administered as a subcutaneous injection, approved in December 2021 for treating well, moderately differentiated, locally advanced, and metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The drug works by mimicking natural somatostatin to inhibit hormone secretion and slow tumor progression. It is indicated to improve progression-free survival in GEP-NET patients and represents a targeted approach to managing this rare oncology indication.
$0.0BPart D
Mechanism of Action
Lanreotide, the active component of Lanreotide Injection, is an octapeptide analog of natural somatostatin. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin.
Indications (2)
Worked on LANREOTIDE ACETATE at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.